OncoMind™ and OncoDecide™
- Equips EBT to navigate complex oncology networks
- Supports access and reimbursement decision-making
- Streamlines commercial activities
- Ensures precision medicine reaches the right physicians and patients
Make a Meaningful Impact on Patient’s Lives
Be the Commercial Partner of Choice to Biotech & Pharma Delivering Innovative Treatments in Rare & Ultra-rare Cancers
Patient-centric, Entrepreneurial, Agile, Lead with Integrity
European Biopharma Therapeutics is a specialty pharmaceuticals platform focused on oncology. EBT was founded in 2022 by Dr. Andreas Penk and Dr. Thomas Rudolph with the involvement of nine additional professionals who have a combined 200+ years of experience in large and medium-sized pharma between them.
EBT is a novel, hybrid quality player combining “Big Pharma”-experienced leaders with a long track record of successful outcomes and high-quality behavior in perceived-to-be risky fields together with a “digital first” operating model leveraging the latest approaches in technology and experienced tech talent.
Business Partners
10
Finished Projects
100
Happy Clients
10
Awards Winning
10
Vision
European Biopharma Therapeutics is a specialty pharmaceuticals platform focused on oncology. EBT was founded in 2022 by Dr. Andreas Penk and Dr. Thomas Rudolph with the involvement of nine additional professionals who have a combined 200+ years of experience in large and medium-sized pharma between them.
EBT is a novel, hybrid quality player combining “Big Pharma”-experienced leaders with a long track record of successful outcomes and high-quality behavior in perceived-to-be risky fields together with a “digital first” operating model leveraging the latest approaches in technology and experienced tech talent.
Over the years, through many product launches and setting up pharmaceutical companies and entities, we have developed an in-depth familiarity with the market and we have a unique network of European oncologists, global KOLs and access to industry-leading knowledge and processes. This allows us to identify and reach the appropriate patients through their physicians and hospitals and ensure delivery of precision medicine.
We have advanced skills and ample resources to create large-scale
Requiem shark snubnose parasitic eel turbot yellow jack loach goby; paperbone, temperate ocean-bass. Armorhead catfish jackfish saber-toothed blenny
Development
85%
Experience
62%
Engeneering
50%
We promise that we never have any commercial incentive while choosing a technology or approach, we base our
PartnersThe Best Partners who Help us
to create TechnUm Startup
